0.1601

2.53% -0.0098

Citius Pharmaceuticals Inc (CTXR)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Perché CTXR Giù? Forum Previsione Frazionamento azionario

Precedente Chiudi:

$0.1699

Aprire:

$0.1694

Volume 24 ore:

3.90M

Relative Volume:

2.50

Capitalizzazione di mercato:

$30.71M

Reddito:

Utile/perdita netta:

$-32.54M

Rapporto P/E:

-0.8005

EPS:

-0.2

Flusso di cassa netto:

$-29.06M

1 W Prestazione:

-49.57%

1M Prestazione:

-56.90%

6M Prestazione:

-77.32%

1 anno Prestazione:

-78.55%

Intervallo 1D:

$0.16

$0.1801

Intervallo di 1 settimana:

$0.16

$0.3279

Portata 52W:

$0.16

$1.07

Citius Pharmaceuticals Inc Stock (CTXR) Company Profile

Nome

Citius Pharmaceuticals Inc

Settore

Healthcare (1195)

Industria

Biotechnology (683)

Telefono

(908) 967-6676

Indirizzo

11 COMMERCE DRIVE, CRANFORD, NJ

Dipendente

Cinguettio

Prossima data di guadagno

2024-08-12

Ultimi documenti SEC

CTXR's Discussions on Twitter

Confronta CTXR con altri titoli

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
CTXR	0.1601	30.71M	0	-32.54M	-29.06M	-0.20
VRTX	448.50	115.43B	10.63B	-479.80M	-1.35B	13.33
REGN	746.23	82.04B	13.85B	4.65B	3.32B	35.06
ARGX	597.88	35.30B	1.86B	-40.29M	-1.28B	-4.16
ALNY	246.48	32.04B	2.09B	-332.26M	16.06M	-4.14
BNTX	108.11	24.89B	3.30B	-501.07M	1.03B	11.54

Citius Pharmaceuticals Inc Stock (CTXR) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2021-11-30	Iniziato	Maxim Group	Buy

Citius Pharmaceuticals Inc Borsa (CTXR) Ultime notizie

Nov 20, 2024

Citius Pharmaceuticals reports positive early stage results of cancer combo treatment - MSN

Nov 20, 2024

Nov 19, 2024

Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) Short Interest Update - Defense World

Nov 19, 2024

Citius Pharmaceuticals (NASDAQ: CTXR) Announces Successful Closure of Offering - Defense World

Nov 19, 2024

Citius Pharmaceuticals Announces Closing of $3 Million Registered Direct Offering - BioSpace

Nov 19, 2024

Nov 18, 2024

Citius Pharmaceuticals Raises $3M in Direct Offering at $0.25 Per Share with Warrants | CTXR Stock News - StockTitan

Nov 18, 2024

Nov 15, 2024

Citius Pharmaceuticals Announces $3 Million Registered Direct Offering - The Malaysian Reserve

Nov 15, 2024

Citius Pharmaceuticals Raises $3M in Direct Offering at $0.25 Per Share | CTXR Stock News - StockTitan

Nov 15, 2024

What is HC Wainwright’s Estimate for CTXR FY2024 Earnings? - Defense World

Nov 15, 2024

Nov 14, 2024

Citius Pharmaceuticals stock hits 52-week low at $0.31 By Investing.com - Investing.com South Africa

Nov 14, 2024

Citius Pharmaceuticals granted extension to regain Nasdaq compliance - Investing.com

Nov 13, 2024

Citius Pharmaceuticals granted extension to regain Nasdaq compliance By Investing.com - Investing.com Australia

Nov 13, 2024

Q1 Earnings Forecast for CTXR Issued By HC Wainwright - MarketBeat

Nov 13, 2024

Nov 12, 2024

Citius Pharmaceuticals (NASDAQ:CTXR) Receives Buy Rating from HC Wainwright - MarketBeat

Nov 12, 2024

Nov 11, 2024

Citius Pharmaceuticals, Inc. and Citius Oncology, Inc. Announce Promising Preliminary Results of an Investigator-Initiated Phase I Clinical Trial of Pembrolizumab (KEYTRUDA®) and LYMPHIR™ in Cancer Patients with Recurrent Solid Tumors - The Malaysian Reserve

Nov 11, 2024

Citius' LYMPHIR Shows Potential To Boost Pembrolizumab Efficacy - Contract Pharma

Nov 11, 2024

Nov 06, 2024

Citius Pharmaceuticals stock hits 52-week low at $0.32 - Investing.com India

Nov 06, 2024

Citius Pharmaceuticals stock hits 52-week low at $0.32 By Investing.com - Investing.com UK

Nov 06, 2024

Citius Pharmaceuticals, Inc. (NASDAQ:CTXR): Is Breakeven Near? - Simply Wall St

Nov 06, 2024

Oct 24, 2024

Citius Pharmaceuticals stock hits 52-week low at $0.34 By Investing.com - Investing.com Australia

Oct 24, 2024

Citius Pharmaceuticals stock hits 52-week low at $0.34 - Investing.com India

Oct 24, 2024

Oct 17, 2024

CTXR (Citius Pharmaceuticals) Cyclically Adjusted Revenue p - GuruFocus.com

Oct 17, 2024

Oct 15, 2024

Investing in Citius Pharmaceuticals Inc (CTXR) might be a great opportunity, but the stock is a bit undervalued - US Post News

Oct 15, 2024

Oct 14, 2024